Zoetis Inc. (NYSE:ZTS) EVP Roxanne Lagano Sells 923 Shares

Zoetis Inc. (NYSE:ZTS) EVP Roxanne Lagano sold 923 shares of Zoetis stock in a transaction that occurred on Thursday, April 18th. The shares were sold at an average price of $151.17, for a total value of $139,529.91. Following the completion of the transaction, the executive vice president now owns 14,800 shares of the company’s stock, valued at $2,237,316. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Roxanne Lagano also recently made the following trade(s):

• On Monday, March 18th, Roxanne Lagano sold 923 shares of Zoetis stock. The stock was sold at an average price of $173.33, for a total value of $159,983.59.
• On Monday, February 12th, Roxanne Lagano sold 363 shares of Zoetis stock. The stock was sold at an average price of $197.74, for a total value of $71,779.62.

Zoetis Stock Performance

NYSE:ZTS opened at $153.11 on Friday. Zoetis Inc. has a 12-month low of $148.48 and a 12-month high of $201.92. The company has a quick ratio of 2.00, a current ratio of 3.36 and a debt-to-equity ratio of 1.32. The firm has a market capitalization of $70.03 billion, a PE ratio of 30.20, a price-to-earnings-growth ratio of 2.32 and a beta of 0.85. The firm has a 50-day moving average price of $176.49 and a 200 day moving average price of $180.20.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, February 13th. The company reported $1.24 earnings per share for the quarter, missing the consensus estimate of $1.32 by ($0.08). The firm had revenue of $2.21 billion for the quarter, compared to analyst estimates of $2.19 billion. Zoetis had a return on equity of 51.25% and a net margin of 27.43%. The business’s quarterly revenue was up 8.5% on a year-over-year basis. During the same period in the previous year, the business posted $1.15 EPS. Research analysts anticipate that Zoetis Inc. will post 5.79 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Friday, April 19th will be issued a dividend of $0.432 per share. This represents a $1.73 annualized dividend and a dividend yield of 1.13%. The ex-dividend date of this dividend is Thursday, April 18th. Zoetis’s payout ratio is 34.12%.

Institutional Trading of Zoetis

Several hedge funds have recently modified their holdings of the stock. Fairfield Bush & CO. bought a new position in Zoetis in the first quarter valued at approximately $134,000. Sequoia Financial Advisors LLC boosted its stake in Zoetis by 5.3% in the first quarter. Sequoia Financial Advisors LLC now owns 4,166 shares of the company’s stock valued at $786,000 after acquiring an additional 211 shares during the last quarter. Candriam Luxembourg S.C.A. boosted its stake in Zoetis by 3.9% in the first quarter. Candriam Luxembourg S.C.A. now owns 51,581 shares of the company’s stock valued at $9,727,000 after acquiring an additional 1,914 shares during the last quarter. Covestor Ltd boosted its stake in Zoetis by 102.8% in the first quarter. Covestor Ltd now owns 724 shares of the company’s stock valued at $137,000 after acquiring an additional 367 shares during the last quarter. Finally, Merit Financial Group LLC boosted its stake in Zoetis by 92.8% in the first quarter. Merit Financial Group LLC now owns 2,342 shares of the company’s stock valued at $442,000 after acquiring an additional 1,127 shares during the last quarter. 92.80% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on ZTS shares. The Goldman Sachs Group upped their target price on Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a research report on Wednesday, January 17th. Barclays boosted their target price on shares of Zoetis from $255.00 to $260.00 and gave the company an “overweight” rating in a research note on Wednesday, February 14th. StockNews.com downgraded shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 20th. Piper Sandler reissued an “overweight” rating and set a $195.00 target price (down from $220.00) on shares of Zoetis in a research note on Tuesday. Finally, Stifel Nicolaus lowered their price target on shares of Zoetis from $215.00 to $195.00 and set a “buy” rating on the stock in a report on Tuesday, April 2nd. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, Zoetis presently has an average rating of “Buy” and a consensus target price of $221.75.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.